Autoimmune thrombocytopenic purpura
Therapeutic area
Immunology
Rare disease
Yes
- Definition
- An autoimmune disorder in which the number of circulating platelets is reduced due to their antibody-mediated destruction. ITP is a diagnosis of exclusion and is heterogeneous in origin.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Autoimmune thrombocytopenic purpura
- Therapeutic area
- Immunology
- autoimmune thrombocytopenic purpura
- immune thrombocytopenia
- ITP
- autoimmune thrombocytopenic purpura
- idiopathic thrombocytopenia
- idiopathic thrombocytopenia purpura
- idiopathic thrombocytopenic purpura
- thrombocytopenic purpura, autoimmune
- AITP
- thrombocytopenic purpura autoimmune
- Severity
- Severe
- Hematology
- Immunology
- MONDO ID
- MONDO:0008558
- Parent condition
- MONDO:0004680
Related records
Broader conditions (16)
- Autoimmune disease
- Autoimmune disorder of blood
- Autoimmune thrombocytopenia
- Blood coagulation disease
- Blood platelet disease
- Disease
- Disease by body system or component
- Hematologic disorder
- Hemorrhagic disease
- Human disease
- Immune system disorder
- Primary thrombocytopenia
- Purpura
- Thrombocytopenia
- Thrombocytopenic purpura
- Thrombotic microangiopathy
Trials (165)
- A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone
- A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788
- A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347
- A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
- A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
- A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
- A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)
- A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura
- A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)
- A PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA PREVIOUSLY TREATED WITH A THROMBOPOIETIN RECEPTOR AGONIST AND/OR RITUXIMAB AFTER CORTICOSTEROID FIRST-LINE THERAPY
- A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
- A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501
- A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
- A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
- A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
- A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
- A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.
- A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
- A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Approved drugs (9)
- Cortisone acetate
- Dexamethasone
- Dexamethasone sodium phosphate
- Eltrombopag choline
- Eltrombopag olamine
- Fostamatinib disodium
- Human immunoglobulin G
- Prednisone
- Romiplostim
Drugs in development (63)
- Acetaminophen Phase 1
- Acetylcysteine Phase 2
- Alemtuzumab Phase 2
- Aspirin Phase 2
- Atorvastatin Phase 2
- Avatrombopag Phase 3
- Baricitinib Phase 2
- Batoclimab Phase 2
- Belimumab Phase 3
- Bevifimod Phase 1
- Blisibimod Phase 2
- Bortezomib Phase 3
- Briobacept Phase 2
- Caffeic acid Phase 3
- Ciprofloxacin Phase 1
- Cyclophosphamide Phase 2
- Cyclosporine Phase 3
- Danazol Phase 2
- Daratumumab Phase 2
- Dazodalibep Phase 1
Other linked drugs (4)
- Esomeprazole magnesium
- Sirolimus
- Valziflocept
- Vonoprazan fumarate